VKTX (STOCKS)
Viking Therapeutics, Inc
$35.150000
+0.890000 (+2.60%)
Prev close: $34.260000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Brian Lian
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $4,044.40M
- Employees
- 51
- P/E (TTM)
- -11.00
- P/B (TTM)
- 6.15
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $393.34M |
| Research and Development | $344.96M |
| Other Operating Expenses | $48.39M |
| Operating Income/Loss | -$393.34M |
| Income/Loss From Continuing Operations After Tax | -$359.64M |
| Income/Loss From Continuing Operations Before Tax | -$359.64M |
| Income Tax Expense/Benefit | $1.00K |
| Net Income/Loss | -$359.64M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$359.64M |
| Net Income/Loss Available To Common Stockholders, Basic | -$359.64M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$3.19 |
| Diluted Earnings Per Share | -$3.19 |
| Basic Average Shares | 112,667,000 |
| Diluted Average Shares | 112,667,000 |
| Assets | $715.73M |
| Current Assets | $715.60M |
| Noncurrent Assets | $131.00K |
| Liabilities | $76.67M |
| Current Liabilities | $76.67M |
| Accounts Payable | $53.25M |
| Other Current Liabilities | $23.42M |
| Noncurrent Liabilities | $0.00 |
| Equity | $639.06M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $639.06M |
| Liabilities And Equity | $715.73M |
| Net Cash Flow From Operating Activities | -$278.69M |
| Net Cash Flow From Operating Activities, Continuing | -$278.69M |
| Net Cash Flow From Investing Activities | $341.39M |
| Net Cash Flow From Investing Activities, Continuing | $341.39M |
| Net Cash Flow From Financing Activities | $76.44M |
| Net Cash Flow From Financing Activities, Continuing | $76.44M |
| Net Cash Flow | $139.14M |
| Net Cash Flow, Continuing | $139.14M |
| Comprehensive Income/Loss | -$358.47M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$358.47M |
| Other Comprehensive Income/Loss | $1.17M |